On Dec. 4, 2025 (updated 2:10 p.m. ET), the federal Advisory Committee on Immunization Practices (ACIP) postponed a decisive vote on whether to change the long-standing recommendation that newborns receive a hepatitis B vaccine within 24 hours of birth. Committee members raised sharp objections to the evidence presented, accusing some speakers of selective use of studies and speculative interpretation. The panel delayed the vote until Friday morning; it was the third postponement as intense disagreements persisted. The dispute unfolded during a meeting convened under a committee slate appointed by Health Secretary Robert F. Kennedy Jr.
Key takeaways
- The ACIP vote on newborn hepatitis B immunization was deferred to Friday morning on Dec. 4, 2025; this was the third delay related to the same question.
- The hepatitis B birth dose is currently recommended within 24 hours after birth to prevent perinatal transmission of a highly infectious virus that can cause severe liver disease.
- Panel format and transparency drew criticism: agenda and work-group names were disclosed late, and presentation files were emailed to media rather than posted publicly before the meeting.
- Nontraditional presenters included Cynthia Nevison (University of Colorado) and Mark Blaxill (an agency staff member), prompting concern about expertise and conflicts; some presenters referenced studies by David Geier, described by critics as discredited.
- Several committee members accused presenters of cherry-picking data and relying on conjecture rather than established scientific evidence, prompting calls for more time to review materials.
- The controversy highlights a broader risk to public trust in vaccine policy if advisory processes appear less transparent or anchored to contested evidence.
Background
The Advisory Committee on Immunization Practices, a federal advisory panel that helps set vaccine policy in the United States, issues recommendations used by clinicians and public-health programs nationwide. For decades ACIP has recommended a hepatitis B vaccine dose for newborns administered within 24 hours of birth to reduce perinatal transmission from mother to infant, a practice credited with substantial reductions in infant and childhood infections.
Historically, scientific presentations at ACIP meetings have been delivered by Centers for Disease Control and Prevention experts or established external investigators, and supporting slide decks and data have been made available to the public in advance. That transparency is intended to let committee members and outside observers evaluate methods, data sources and assumptions before votes on policy changes.
Main event
At the Dec. 4 session, members challenged the meeting format and the provenance of evidence. Organizers did not list speakers on the agenda until the morning of the meeting and disclosed the hepatitis B work-group membership only after participants pressed for the names. Committee members also noted that supporting materials were not posted in the usual public repository; instead, files were distributed by email to reporters.
Two presenters who are not CDC vaccine scientists drew particular attention. Cynthia Nevison, a researcher at the University of Colorado who previously served on the board of SafeMinds, presented analyses of disease-trend data; critics noted her prior association with an advocacy organization that has questioned vaccine safety. Separately, Mark Blaxill—described in public records and reporting as an anti-vaccine activist who now holds a staff role at the agency—presented safety-related material that relied in part on studies published by David Geier, a researcher whose vaccine-related work has been widely criticized.
Several ACIP members publicly objected to what they characterized as selective citation of studies and inference beyond what the data could support. Those objections slowed discussion and led multiple members to request additional time to review the evidence and supplemental materials before a binding vote. Because consensus could not be reached on whether the submissions met the committee’s evidentiary standards, the panel postponed the vote until Friday morning.
Analysis & implications
Procedural departures and the choice of presenters injected uncertainty into a policy process that normally rests on transparent, peer-reviewed evidence. If ACIP were to amend or remove the universal newborn hepatitis B recommendation, the change would have immediate clinical implications for hospital birth practices and state newborn vaccination programs that rely on ACIP guidance.
Public confidence in routine immunization schedules rests partly on the perception that recommendations are evidence-driven and subject to independent scientific review. Perceived erosion of those norms could reduce trust among clinicians, parents and public-health systems, particularly for an intervention administered in the first day of life.
Any policy reversal could also carry measurable health consequences: declines in birth-dose coverage could increase the risk of perinatal hepatitis B transmission, particularly in births to mothers with undiagnosed infection. Conversely, stronger scrutiny of post-licensure safety data and clearer transparency about materials and methods could strengthen policy credibility if handled openly.
Politically, the episode highlights how appointment choices and meeting procedures can affect technical deliberations. The committee’s composition—appointed by the health secretary—has become part of the debate over whether advisory bodies retain institutional independence in contentious policy decisions.
Comparison & data
| Element | Current practice | Recent meeting status |
|---|---|---|
| Newborn hepatitis B dose | Administer within 24 hours of birth (universal recommendation) | Vote on recommendation deferred; three postponements as of Dec. 4, 2025 |
| Meeting transparency | Past practice: advance posting of slides and work-group names | Agenda and work-group names released late; materials emailed to press |
The table shows the contrast between established procedural norms and the departures reported at the Dec. 4 meeting. Although the core clinical recommendation remains unchanged until a formal vote, interruptions and procedural disputes extend the timeline for any policy decision.
Reactions & quotes
“This session resembled political theater more than a standard scientific deliberation,”
Outside expert
“Presenters were accused of cherry-picking data and substituting speculation for science,”
Several ACIP members
Those reactions encapsulate the central criticism driving the delay: committee members said they needed clearer, verifiable evidence presented in a conventional scientific format before voting on a recommendation that affects universal newborn care.
Unconfirmed
- Whether the committee will ultimately vote to remove or substantially alter the universal newborn hepatitis B recommendation remains unresolved; no final decision has been recorded.
- The extent to which the health secretary’s appointments influenced specific evidentiary choices at the meeting has not been independently verified.
- Allegations about the reliability of particular studies cited at the meeting are still under review by committee members and external reviewers.
Bottom line
The Dec. 4, 2025 ACIP meeting underscored a clash between procedural norms and a contentious evidentiary record presented to the panel. For now, the universal recommendation for a hepatitis B dose within 24 hours remains in place pending the rescheduled vote and any further review of the materials.
Observers should watch the Friday vote, the release of full supporting materials and any formal statements from CDC technical staff; those developments will determine whether hospitals and state programs must prepare for a policy shift or whether greater transparency and additional review will restore confidence in the advisory process.